Latest news with #JohnsonJohnson
CTV News
5 hours ago
- Business
- CTV News
Popular contacts brand recalls lenses over ‘visual disturbances' defect
A popular contacts manufacturer is recalling several lenses in Canada over a defect that may cause 'visual disturbances.' The voluntary recall is due to an issue with specific types and lots of Acuvue contacts, according to a notice posted Friday. U.S. based manufacturer Johnson & Johnson said in the notice posted by Health Canada that some Oasys Max 1-Day Multifocal contact lenses were found to have a 'high density of microbubbles.' The company explained this as 'microscopic voids' within the lenses that may cause what it described as 'visual disturbances, particularly in low-light conditions.' Johnson & Johnson said microbubbles will not cause medical harm and told wearers to contact it for more information. The company did not say how many of the affected lots were sold in Canada, when they were sold or through which retailers. Acuvue contacts recall ( Lenses of the same name appear to be sold online on sites like and Costco, as well as through eye clinics. The recall does not apply to all Oasys Max 1-day Multifocal contact lenses, but is limited to the following lot and model numbers:
Yahoo
11 hours ago
- Business
- Yahoo
Addex Therapeutics Ltd (ADXN) Q1 2025 Earnings Call Highlights: Strategic Advances and ...
Cash Balance: CHF2.8 million as of March 31, 2025. Cash Runway: Expected to last through mid-2026. Continuing R&D Expenses: CHF0.1 million, primarily related to the GABAB PAM program. Continuing G&A Expenses: CHF0.5 million, primarily related to corporate loan activities. Net Loss from Discontinued Operations: Specific line item due to divested business. Current Liabilities: CHF1.1 million as of March 31, 2025. Non-Current Liabilities: CHF0.1 million as of March 31, 2025. Equity Interest: 20% equity interest in a divested business, recorded under non-current assets. Warning! GuruFocus has detected 6 Warning Signs with ADXN. Release Date: June 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Addex Therapeutics Ltd (NASDAQ:ADXN) has made significant progress in its GABAB positive allosteric modulator program with partner Indivior, completing IND-enabling studies for substance use disorders. The company regained rights to its mGluR2 positive allosteric modulator program from Johnson & Johnson, opening new therapeutic opportunities. Addex Therapeutics Ltd (NASDAQ:ADXN) has repositioned its mGluR5 negative allosteric modulator program for brain injury recovery, with promising preclinical data supporting its potential. The company has a strong cash position with CHF2.8 million, providing a runway through mid-2026, and has reduced cash burn following the Neurosterix spinout. Addex Therapeutics Ltd (NASDAQ:ADXN) has a robust pipeline with multiple programs advancing, including a promising candidate for chronic cough with favorable preclinical efficacy and tolerability. The current cash position does not fund the progression of unpartnered programs into the clinic, indicating potential future financing needs. Revenue decreased compared to the previous year due to the completion of the funded research phase with Indivior, impacting financial performance. The company faces competition in the chronic cough market, with existing compounds showing promising efficacy but challenging tolerability profiles. There is uncertainty regarding the clinical development pathway and competitive landscape for the chronic cough program, which could impact future success. Addex Therapeutics Ltd (NASDAQ:ADXN) needs to conduct further studies to optimize the use of dipraglurant in post-stroke rehabilitation, indicating a longer timeline before potential market entry. Q: Can you provide your updated thoughts on the current competitive landscape in chronic cough and the relevance of proceeding programs for your clinical development pathway? A: Mikhail Kalinichev, Head of Translational Science, explained that there are several compounds in development, such as now roofing, which has shown promising efficacy but with tolerability challenges. Addex aims to deliver similar efficacy with improved tolerability, targeting both IPF-related and refractory chronic cough. The development plan includes studies in healthy volunteers and a challenge study in chronic cough patients, followed by a Phase 2 study with advanced monitoring technologies. Q: Can you comment on the potential applicability of your agent for chronic painful cough in indications outside of IPF, like pulmonary sarcoidosis? A: Mikhail Kalinichev noted that chronic painful cough could be a suitable indication due to the sustained activation of GABAB across multiple conditions, including chronic cough. Tim Dyer, CEO, added that they are considering this indication for Phase 2 development. Q: Regarding dipraglurant in post-stroke rehabilitation, what would an appropriate control arm look like in a registration-quality study, and what is the efficacy bar in this indication? A: Mikhail Kalinichev stated that dipraglurant would be used alongside physiotherapy due to its short half-life and good tolerability. They plan to conduct clinical pharmacology studies to understand its modulation effects better, which will inform the design of a Phase 2 study. The efficacy bar is challenging as no pharmacotherapies are currently approved in this context. Q: Can you elaborate on the strategic importance of your GABAB positive allosteric modulator program with Indivior? A: Tim Dyer highlighted the program's potential to deliver a better baclofen for substance use disorders, with a longer half-life and improved side effect profile. The partnership with Indivior is crucial, as it allows Addex to advance its own independent GABAB PAM program for chronic cough, leveraging the strong rationale for GABAB PAMs in this area. Q: What are the financial implications of your recent achievements and strategic partnerships? A: Tim Dyer reported that Addex completed Q1 2025 with CHF2.8 million in cash, providing a runway through mid-2026. The cash burn has been reduced following the Neurosterix spinout, and the company is well-positioned to deliver on strategic objectives, including advancing their pipeline and exploring new partnerships. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
a day ago
- Business
- Yahoo
Jets owner Woody Johnson wants to buy an English Premier League soccer team
New York Jets owner Woody Johnson is among the most controversial figures in North American sports. Among the heirs to the Johnson & Johnson pharmaceutical fortune, Johnson purchased the Jets for $635 million alongside his brother Christopher Johnson in 2000. He's now setting his sights on expanding his ownership by attempting to purchase a soccer team. Johnson has reportedly made an offer to purchase a 43 percent stake in English Premier League (EPL) club Crystal Palace, according to a report by The Telegraph. Crystal Palace's estimated value is said to be approximately £500 million. This isn't Johnson's first attempt to purchase an English soccer club. The former United Kingdom Ambassador made an approach to purchase Chelsea FC in 2022. He was unsuccessful, but is now reigniting his interest by taking a run at a stake in Crystal Palace's ownership structure. Advertisement Crystal Palace finished 12th in the EPL standings this past season. As winners of the FA Cup this year (an in-league Cup competition), they qualified for the Europa League next season, the second-most prestigious European-wide competition. That'll bring more revenue and notoriety to the club in 2025. Crystal Palace has never won the Premier League. Doesn't Johnson already own enough underperforming teams? This article originally appeared on Jets Wire: Jets rumors: Owner Woody Johnson wants to buy an English soccer team
Yahoo
3 days ago
- Business
- Yahoo
Trump's big beautiful bill: What the pharma industry is watching
Pharmaceutical stocks, including Pfizer (PFE), Johnson & Johnson (JNJ), Abbvie (ABBV), Novo Nordisk (NVO), and Astrazeneca (AZN), are falling after President Trump said tariffs on the industry are coming "very soon." Chris Meekins, managing director and Washington health policy research analyst at Raymond James, joins Market Domination to discuss potential tariffs and explain how President Trump's tax bill could affect the pharmaceutical industry. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. And speaking of Congress, Chris, uh, we didn't even really talk about the, the big beautiful bill, right? So I'm curious from a healthcare policy perspective, what is the thing that you're watching most closely within that bill? Yeah, for the pharmaceutical industry, there were some changes to the Orphan Drug Act that would have been more favorable to them in the house bill. Did not get included in the Senate bill. We'll be watching those developments. But the biggest focus has really been on Medicaid provider taxes and state directed payments, which are very nichey, matter to hospitals, matter toward how these facilities are being funded, um, to make up for what are historically lower Medicaid payments compared to other payments. A lot of focus there, well, we will see a very interesting dynamic where the bill may cut or save a trillion dollars in healthcare spending, but when you peel back the onion, the direct impact to state budgets is probably less than $200 billion over a decade. And for providers, it's probably a fraction of that because we think the CBO's estimates for how many people are going to become uninsured are probably double what they end up being. CBO are very nice people. They just tend to be off by orders of magnitude that would get either of us fired if we were consistently that wrong when it came to, um, projecting what enrollments going to be in healthcare programs. Wow, shade against the CBO, Chris. Thanks so much for being here as always. They gave me a bad CBO score when I was a staffer. I've not gotten over it. Oh, well, understood, understood. Thanks a lot, Chris. Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
Trump's big beautiful bill: What the pharma industry is watching
Pharmaceutical stocks, including Pfizer (PFE), Johnson & Johnson (JNJ), Abbvie (ABBV), Novo Nordisk (NVO), and Astrazeneca (AZN), are falling after President Trump said tariffs on the industry are coming "very soon." Chris Meekins, managing director and Washington health policy research analyst at Raymond James, joins Market Domination to discuss potential tariffs and explain how President Trump's tax bill could affect the pharmaceutical industry. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.
